Blueprint Medicines Investor Relations Material
Latest events
Q4 2023
Blueprint Medicines
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Blueprint Medicines Corp
Access all reports
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. It focuses on the discovery, development, and commercialization of small molecule therapies for patients with diseases caused by genetic mutations. The company's pipeline products include, among other, BPX-501 that targets Caskin 1; BPX-701 that is involved in targeting patients with Ras (RAS) inhibitor-refractory or -intolerant melanoma; BPX-601 that is involved in targeting basal cell carcinoma; BPX-302 that targets Bcr/Abl fusion proteins; and BPX-401 that targets NY-ESO-1.
Key slides for Blueprint Medicines Corp
Q4 2023
Blueprint Medicines Corp
Q4 2023
Blueprint Medicines Corp
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States